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Genetic modification of haematopoietic stem/progenitor cells 
(HSCs) for therapeutic applications has been in development for 
over 30 years, and two such treatments were recently granted 
market authorisation by the European Medicines Agency. The first, 
designated GSK2696273 (commercially known as Strimvelis 
(GlaxoSmithKline (GSK), UK)), is indicated for treatment of a 
rare primary immune disorder, known as adenosine deaminase-
deficient severe combined immunodeficiency (ADA-SCID).[1] 
Following transplantation of autologous gene-modified HSCs 
expressing functional ADA, a 100% survival over a median follow-
up of seven years was shown for 18 study participants.[2] The second 
treatment, BB305 (Zynteglo, Bluebird Bio, USA), is based on the 
replacement of functional beta-haemoglobin in HSCs from patients 
with transfusion-dependent beta-thalassaemia. Data from clinical 
development show that patients treated with Zynteglo achieved either 
complete transfusion independence or a near two-thirds reduction 
in the annual number and volume of blood transfusions.[3] Together 
with the approval of three other gene modification therapies in 
2017 – namely two chimeric antigen receptor (CAR) T cell therapies 
against B cell malignancies (axicabtagene ciloleucel (Gilead-Kite 
Pharma, USA), and tisagenlecleucel (Novartis, Switzerland), as 
well as Luxturna (Spark Therapeutics, USA)) for an inherited form 
of vision loss – a new era of modern medicine has been entered 
into where one can imagine the use of ‘single-treatment cures’ for 
life-threatening and previously incurable diseases. The journey to 
approval of these therapies has by no means been trivial. Notable 
advances in the technologies and treatment regimens have been 
made, and credit is due to the scientists, clinicians, institutions and 
regulators who laid the foundation for future approvals. A description 
and key aspects relating to successful implementation of HSC gene 
therapies are highlighted in this review. 
Rationale
Haematopoietic stem cell transplantation (HSCT) is a globally 
accepted practice for the treatment of malignant and non-malignant 
disorders of the blood and immune systems. Almost 90% of HSCTs 
worldwide are done for the treatment of haematological malignancies, 
including leukaemia, lymphoma and myeloma.[4,5] For these cases, 
patients initially receive a chemotherapy regimen to destroy tumour 
cells, but since the treatment targets all rapidly dividing cells in the 
body, it also depletes the HSC compartment in the bone marrow. The 
HSCT is thus aimed at replenishing the bone marrow with stem cells, 
which engraft and reconstitute the immune system with functional 
haematopoietic lineages. For non-malignant conditions, primarily 
rare inherited diseases of the blood and immune systems, the 
rationale for HSCT is to provide the patient with a haematopoietic 
lineage that replaces or compensates for the underlying genetic 
deficiency. Allogeneic HSCT, i.e. transplantation of HSCs harvested 
from a healthy donor, is essentially the only option for cure of these 
disorders. This however comes with notable limitations and safety 
concerns, including the need for a genetically matched donor (which 
may not be available for up to 70% of cases), graft rejection, delayed 
immune reconstitution, graft-versus-host disease and a significant 
rate of mortality. Autologous transplantation of the patient’s own 
HSCs, which have been gene-modified to correct for the underlying 
genetic cause of the disease, would thus be the preferred form of 
treatment for these patients. 
Scope of treatment
Fundamentally, all inherited disorders of the blood and immune 
systems can be treated with gene-modified HSCs, provided 
that the underlying genetic cause is known and it is feasible for 
correction, i.e. gene modification to correct multiple aberrations 
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in different genes is presently not feasible. These include primary 
immune deficiencies, haemoglobinopathies, lysosomal storage and 
metabolic diseases, and bone marrow failure syndromes – many 
of which are today treated with allogeneic HSCT. The primary 
immune deficiencies were the prototype indications treated with 
gene-modified HSCs.[6] More specifically, these included ADA and 
X-linked SCID, Wiskott-Aldrich syndrome (WAS) and chronic 
granulomatosis disease (CGD). Following successful transplantation 
and engraftment of gene-modified HSCs, together with long-term 
functional expression of the therapeutic genes, these initial studies 
provided proof of principle that HSC gene therapy is indeed a 
rational and feasible treatment approach. In addition to the approvals 
mentioned previously (Strimvelis (GSK, UK) and Zynteglo (Bluebird 
Bio, USA)), many such treatments are in pre-clinical and clinical 
development for various indications (Table 1), and it is estimated that 
over 200 patients with inherited disorders have been treated to date 
with gene-modified HSCs. 
There is a notable broadening in the scope of treatment, and the 
transplantation of gene-modified HSCs is also suitable for application 
in strategies other than the replacement of a defective gene. For 
example, it is well established that the C-C chemokine receptor 
type 5 (CCR5) co-receptor is a promising target for preventing 
HIV infection. In a single case of HIV cure, the so-called Berlin 
patient received an allogeneic transplantation of HSCs from a 
CCR5-null donor for reconstitution of his immune system following 
myeloablative chemotherapy for the treatment of leukaemia.[7] 
Inspired by these findings, numerous groups, including ours, 
have developed novel strategies to gene-modify patient HSCs for 
autologous transplantation and the subsequent generation of an HIV-
resistant immune system.[8] CCR5 expression can be obviated via 
gene-silencing approaches, i.e. the integration of short hairpin RNA 
(shRNA) or microRNA constructs, or the gene itself can be disrupted 
via gene-editing modalities (see below). In pre-clinical studies, this 
approach has led to a functional cure of HIV,[9] while clinical studies 
to assess their safety and efficacy are still underway. 
Successful HSC gene therapy ultimately depends on the ability to 
engraft adequate numbers of gene-modified HSCs that will persist in 
the long term and express therapeutic genes in all cells of the blood 
lineages. The treatment procedure is however complex and various 
aspects require careful consideration, including: (i) the collection of 
high numbers of HSCs; (ii) safe and efficient cell processing; and (iii) 
optimal transplantation protocols. Fig. 1 illustrates these concepts, 
including schematic summaries of relevant gene-modification 
techniques. 
Table 1. List of gene-modified HSC therapies in development (non-exhaustive)
Therapeutic area Disease Development stage
Primary immune deficiencies Severe combined immunodeficiency
• Adenosine deaminase deficient
• X-linked
• Other (RAG1, RAG2, Artemis)
Approved (2016)*
Clinical
Pre-clinical
Chronic granulomatous disease
• X-linked
• Autosomal recessive
Clinical 
Pre-clinical
Wiskott-Aldrich syndrome Clinical
Leukocyte adhesion deficiency Pre-clinical
Hyper IgM syndrome Pre-clinical
Lymphoproliferative disease Pre-clinical
Agammaglobulinaemia Pre-clinical
Haemophagocytic lymphohistiocytosis
• Perforin deficiency
• Munc13-4 deficiency
Pre-clinical
Pre-clinical
Haemoglobinopathies Beta-thalassaemia Approved (2018)†
Sickle cell disease Clinical
Lysosomal storage and metabolic 
disease
Adrenoleukodystrophy Clinical
Gaucher disease and other lipidoses Clinical
Metachromatic leukodystrophy Clinical
Mucopolysaccharidoses (MPS)
• MPS I (Hurler syndrome)
• MPS II - IV
Clinical
Pre-clinical
Bone marrow failure syndromes Fanconi anaemia Clinical
Schwachman-Diamond syndrome Pre-clinical
Kostmann’s syndrome Pre-clinical
Other indications HIV (CCR5-targeting) Clinical‡
RAG = recombination activating gene; IgM = immunoglobulin M; CCR5 = C-C chemokine receptor type 5.
*Strimvelis (GlaxoSmithKline, UK), approved by the European Medicines Agency, is based on the use of gamma-retroviral gene transfer of adenine deaminase. Equivalent treatments using 
lentiviral vectors for gene modification of HSCs are also in clinical development.[33]  
†Zynteglo (Bluebird Bio, USA), approved by the European Medicines Agency.  
‡Includes groups using short hairpin RNA (shRNA) and gene-editing approaches (zinc finger nucleases and clustered regularly interspaced short palindromic repeats (CRISPR)).
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Collection of HSCs
HSCs are multipotent stem cells, generally defined by their expression 
of the CD34 antigen, and mainly reside in the bone marrow, where 
conditions are optimal for haematopoiesis. Since HSCs constitute less 
than 0.1% of cells in peripheral circulation, they have traditionally 
been harvested directly from the bone marrow via the iliac crest. 
As an alternative, HSCs can be harvested from the peripheral 
blood following treatment with haematopoietic growth factors, such 
as granulocyte-colony-stimulating factor (G-CSF; also known as 
neupogen or filgrastim), which stimulate HSC cycling and thereby 
significantly increase numbers in the peripheral blood. In Europe 
and the US, ~90% of HSCTs are performed using peripheral blood 
mobilised HSCs.[4,5] In a typical HSC collection from peripheral 
blood, donors will receive G-CSF twice daily over 4 - 5 days, followed 
by harvesting via leukapheresis. A leukapheresis unit contains all 
the white blood cells, which have been separated from plasma and 
red blood cells based on density centrifugation. In addition to the 
CD34+ HSC population, the white blood cell compartment contains 
lymphocytes, granulocytes and monocytes. 
It is important that adequate numbers of CD34+ cells are harvested 
from the patient to compensate for inevitable losses in the 
downstream processing and preparation of the final drug product. 
A patient collection should thus yield over 6 million CD34+ cells 
per kg to ensure that a minimum number of 3 - 5 million gene-
modified cells per kg are finally re-introduced to the patient. This 
is often achieved in patients mobilised with G-CSF, but not in 
all cases, such as in those with sickle cell disease,[10] where HSCs 
mobilise rather poorly with G-CSF, which results in an insufficient 
number of CD34+ cells being collected. More recently, plerixafor 
(an inhibitor of C-X-C chemokine receptor type 4 (CXCR4), a 
receptor responsible for the homing of HSCs to the bone marrow) 
has been used to either complement G-CSF mobilisation or on its 
own, which has resulted in substantial increases in CD34+ stem 
cell harvests. Plerixafor has a favourable safety profile and requires 
either a single dose (or at most one additional dose) to achieve 
CD34+ cell mobilisation in adequate numbers.[11] Even so, in cases 
such as Fanconi anaemia it is still difficult to obtain adequate 
numbers of CD34+ cells.[12]
Patient COLLECTION
Mobilisation of HSCs
G-CSF and/or Plerixafor
TRANSPLANTATION
Pre-conditioning
Low-dose chemotherapy or monoclonal 
antibodies against c-Kit/CD47/CD45
Leukapheresis unitGene-modified 
CD34-positive cells
CELL PROCESSING
HSC enrichment
Separation of CD34-positive cells
Gene modification of CD34 positive cells
Viral and non-viral
Viral vectors
(lentiviral and gamma-retroviral)
Viral vector carrying 
therapeutic gene
Patient DNA
Viral 
integrase
Transduction of 
patient cells
Viral RNA 
Reverse 
transcription
Viral DNA 
Insertion
(semi-random)
Gene editing 
(ZFNs, TALENs, meganucleases, CRISPR)
Double-stranded break
NHEJ
HDR
Gene disruption via the 
introduction of indels
Directed insertion of DNA
(therapeutic genes or correction of 
pathogenic  mutations)
Donor DNA
Patient DNA
Targeted to a specific 
DNA sequence
Endonuclease
Transposon-mediated
(Sleeping Beauty, PiggyBac, Tol2)
Transposon-carrying therapeutic gene
Excision
Donor DNA
Insertion
(semi- to near-random)
Patient DNA
ITRITR
Transposase
Fig. 1. Haematopoietic stem cell gene therapy. Considerations for the collection, cell processing and transplantation are provided. A schematic overview of the 
different approaches used to gene-modify patient cells is also provided, namely the use of viral vectors and non-viral approaches (gene editing and transposon-
mediated). (CRISPR = clustered regularly interspaced short palindromic repeats; G-CSF = granulocyte-colony-stimulating factor; HDR = homology-directed 
repair; HSC = haematopoietic stem and progenitor cells; ITR = inverted terminal repeat; NHEJ = non-homologous end joining; TALENs = transcription 
activator-like effector nucleases; ZFN = zinc finger nucleases.)
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Cell processing
The leukapheresis unit, containing all white blood cells, carries up 
to 60 billion cells in volumes of up to 400 mL. The initial processing 
of patient cells includes separation of the CD34+ population using 
anti-CD34 antibody bound to paramagnetic particles/beads. Once 
added to the leukapheresis unit, the beads bind to cells expressing 
extracellular CD34, which can then be positively selected for using 
a magnet and a series of washing procedures to first remove all the 
unwanted cells (monocytes, granulocytes and other lymphocytes) 
and then to dissociate the magnetic beads from the enriched 
CD34+ population. For clinical grade and scale cell separation, 
specific equipment such as the CliniMACS (Miltenyi Biotec, 
Germany) is required, which is reported to yield recovery rates 
of ~70% and purities of over 95%.[13] The CliniMACS Prodigy, 
a next-generation device, has additional functionalities that 
facilitate gene modification of patient cells, making it the preferred 
instrument for gene therapy applications. These devices are 
certified for cell therapy applications and globally accepted by 
regulatory authorities.[14,15] However, the system is costly and has 
low throughput, which will have its challenges if we are to foresee 
roll-out of ex vivo gene-modified cell therapies for diseases such 
as HIV and sickle cell disease where the patient burden is in the 
millions and is often in lower-to-middle income countries. There is 
thus an opportunity to address these limitations with more efficient 
process developments, lower cost and higher throughput equipment 
solutions. 
Broadly speaking, two strategies for gene modification of 
HSCs are applied, namely viral and non-viral (Table 2). Viral 
vectors (in particular lentiviral and gamma-retroviral vectors) 
are well-established technologies, and both the approved HSC 
gene therapies (Strimvelis and LentiGlobin) make use of these 
approaches for gene modification of patient cells. The recently 
approved chimeric antigen receptor (CAR) T cell therapies also 
make use of viral vectors.[16] Although far less well established, non-
viral approaches comprising gene editing and transposon-based 
technologies are believed to hold great promise for future clinical 
applications. 
Viral vector gene modification
Viral vectors form the cornerstone of gene-modified cell therapies. 
They are derived from natural viruses, but have been reconstructed 
to infect and optimally deliver genetic material to target cells. To 
make them clinically viable, several elements of the viral genome 
have been adapted to render them self-inactivating, which prevents 
viral propagation. Many varieties of viral vectors exist, some of 
which allow for integration of therapeutic genes (e.g. retroviral and 
lentiviral), while others deliver genetic material for a transient effect 
(e.g. adeno- and adeno-associated viral vectors). The latter group of 
vectors is also employed by gene-editing and transposon modalities 
for transient delivery of their respective components (see non-viral 
gene modification section below). 
For integration of therapeutic genes, gamma-retroviral and 
lentiviral vectors are mainly used, with the latter being the vector of 
choice for gene modification of cells of the haematopoietic system. 
Following transduction (infection) of patient cells, the viral RNA 
is converted to DNA by reverse transcriptase and then integrated 
into the cellular genome in a semi-random fashion using the 
integrase enzyme provided by the viral vector. The primary concern 
for using viral vectors is one of safety, in particular insertional 
mutagenesis. Initial clinical studies showed that HSC gene therapy 
using gamma-retroviral vectors was curative for the majority of 
primary immune deficiency patients (with ADA-SCID, X-SCID, 
WAS and CGD), but they were later marred by the occurrence of 
treatment-related haematological malignancies. After 2 years of 
follow-up, 25% of the patients presented with myelodysplasia or 
leukaemia due to insertional mutagenesis caused by the gamma-
retroviral vectors.[6] Essentially, gamma-retroviral vectors typically 
insert near proto-oncogenes, which resulted in their activation and 
malignant transformation of the gene-modified cells. Interestingly, 
with over 45 patients treated to date, no ADA-SCID patients receiving 
gene therapies with gamma-retroviral vectors have thus far developed 
malignancies. The reasons for this remain unclear. 
Following these studies, numerous advances in viral vector-
mediated gene transfer have been made, including the implementation 
and acceptance of lentiviral vectors as the vector of choice.[17] 
Table 2. Advantages and disadvantages of gene transfer systems used for gene modification of HSCs
System Advantages Disadvantages
Viral vectors* Established technology and the basis of all currently 
approved ex vivo gene-modified cell therapies†
Risk of insertional mutagenesis (when using gamma-
retroviral vectors) 
Favourable safety profile (generally accepted for 
lentiviral vectors)
Laborious and costly to manufacture
High efficiency gene modification of HSCs (following 
protocol optimisation)
Gene editing‡ Targeted (non-random) editing of cells New technology with limited use in clinical studies
Versatile – allows for gene insertion, correction of 
pathogenic mutations and gene disruption
Risk of off-target effects and cellular toxicity
Low efficiency gene modification of HSCs
Laborious and costly to manufacture§
Transposons Low immunogenicity New technology with limited use in clinical studies
Affordable to manufacture Low efficiency gene modification of HSCs
Risk of off-target effects and cellular toxicity
HSCs = haematopoietic stem cells. 
*Viral vectors generally include lentiviral and gamma-retroviral vectors.  
†Strimvelis for ADA-SCID, Zynteglo for beta-thalassaemia, axicabtagene ciloleucel for acute lymphoblastic leukaemia and tisagenlecleucel for diffuse large B cell lymphoma. 
‡Gene-editing systems include zinc finger nucleases (ZFNs), transcription activator-like effector nucleases (TALENs), meganucleases and clustered regularly interspaced short palindromic 
repeats (CRISPR)-associated Cas. 
§Gene-editing approaches often also make use of viral vectors adapted for transient delivery of the gene-editing nucleases, which increases costs.
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Lentiviral vectors are associated with low immunogenicity and have 
been shown to integrate more randomly into the genome without 
risk of insertion near proto-oncogenes. In comparison with gamma-
retroviral vectors, it has been shown that lentiviral transduction of 
HSCs results in integration at over 1 500 insertion sites relative to 
less than 100 for gamma-retroviral vectors.[18,19] The most important 
conclusion to be made from these studies is that lentiviral vectors 
are far less prone to interfering with genes which result in HSC 
transformation. The situation is thus entirely different for lentiviral 
vectors, with no cases of insertional mutagenesis being reported to 
date. Notably, HIV belongs to the family of lentiviruses, and even with 
all the cases of HIV infection recorded to date, there have been no 
reports of haematological malignancies due to insertional mutagenesis. 
Additional benefits of lentiviral vectors are that they are able to 
infect a broader range of target cells, including non-dividing cells. 
The latter is particularly relevant in the context of HSCs, which 
typically transduce poorly when compared with other cells of the 
haematopoietic system, such as T cells. Even with lentiviral vectors, 
transduction rates can be as low as 10% in CD34+ cells compared with 
>90% in T cells when using equivalent ratios of vector to target 
cells (referred to as multiplicity of infection (MOI)). Optimisation 
of lentiviral transduction protocols over the years has resulted 
in significant improvements in transduction rates, including the 
use of high MOIs (>100), transduction over 2 consecutive days, 
optimised growth media and cytokine usage,[18-20] and transduction 
enhancers.[21,22] 
Non-viral gene modification
Gene editing also allows for the insertion of a therapeutic gene, but 
with the added advantage of being able to do so in a targeted fashion. 
The technology is based on a joint delivery of guiding elements (DNA 
binding) and an endonuclease enzyme, which allow one to target 
and cut genomic DNA in a highly specific manner. In addition to 
gene insertion, the ability to direct endonuclease activity means that 
gene editing further allows for the correction of genes at the site of 
a pathogenic mutation or the disruption of therapeutically relevant 
genes (such as CCR5 for HIV). Following a targeted double- stranded 
break of DNA, gene-editing techniques rely (and capitalise) on the 
natural mechanisms of DNA repair in the cell. Homology-directed 
repair (HDR) enables insertion of genetic material, which can be 
entire therapeutic genes or shorter fragments for correction of 
pathogenic mutations. Gene disruption relies on non-homologous 
end joining (NHEJ) to simultaneously integrate small insertions or 
deletions into a target gene, thereby resulting in a shift in the reading 
frame and subsequent loss of function. Therefore, relative to viral 
vector gene modification, gene editing is a more versatile technology 
by virtue of it being a site-directed modality. 
Four broadly categorised mechanisms of gene editing exist, 
namely zinc finger nucleases (ZFNs), transcription activator-like 
effector nucleases (TALENs), meganucleases and clustered regularly 
interspaced short palindromic repeats (CRISPR)-associated Cas. 
Each varies mechanistically in the way it targets and edits genomic 
DNA, construction and manufacturing complexity, as well as in 
editing efficiencies.[23] In the context of HSC gene modification, 
gene-editing techniques are generally poorly efficient relative to viral 
vectors. These new technologies are still undergoing ‘growing pains’ 
and key safety issues are still to be resolved before clinical application 
can unequivocally be considered viable. The most notable challenge 
is the risk of off-target effects, which could result in functional 
impairment or decreased fitness of edited cells, or more relevantly 
introduce pro-oncogenic risks.[23,24] 
Transposon-based systems make up the second class of non-viral 
gene-modification strategies. Transposons are naturally occurring 
and mobile DNA elements that have the ability to change their 
positions in the genome. Within their structure, they have a 
recognition domain for transposase – the enzyme performing the 
‘cut and paste’ function – and are flanked by inverted terminal 
repeat sequences. Once the DNA element is excised, it is re-inserted 
in a semi-random fashion across the genome.[25] For therapeutic 
application, a transposon carrying the therapeutic gene is provided 
by a synthetic DNA donor strand. Following excision via transposase, 
the transposon is inserted in a semi-random manner in the genome 
of patient cells. Three transposon-based systems have been developed 
for therapeutic purposes, namely Sleeping Beauty, PiggyBac and 
Tol2. Each differ in their origins and have specific advantages and 
disadvantages. Sleeping Beauty seems to integrate in a closer-to-
random manner across the genome, whereas the other two tend to 
integrate in a profile similar to that of gamma-retroviral vectors.[26,27] 
PiggyBac and Tol2 have the ability to carry larger genetic cargos, while 
PiggyBac is the most efficient with the highest transposition activity. 
At present, transposon-mediated gene modification is still relatively 
inefficient, and as is the case for viral vectors and gene editing 
modalities, gene transfer to HSCs remains the biggest challenge. 
Significant advances have been made recently,[25,27] and considering 
the advantages and simplicity of the technology, it is foreseen that this 
will remain a promising alternative and part of the future landscape of 
gene-modified cell therapies. Notably, a transposon-based system is 
being successfully applied for creating CAR T cells, with development 
being in clinical trial stages.[25,28] 
Transplantation
‘Conditioning’ of patients prior to HSCT is essential for successful 
engraftment of HSCs. The principle is based on the premise of 
creating a niche within the bone marrow (by depleting proliferating 
HSCs) where the transplanted HSCs are able to home and engraft. 
Various conditioning regimens exist and the decision on which to 
use depends on the disease being treated, the stage of the disease 
and the patient’s medical status. Conditioning regimens can be in the 
form of total body irradiation and/or cytotoxic/chemotherapeutic 
agents, and can be administered at high doses to achieve maximal 
ablation (myeloablation) of the bone marrow or at low doses for 
reduced-intensity conditioning (RIC) purposes. For allogeneic HSCT, 
the conditioning regimens may also include immunosuppressive 
treatments to prevent graft rejection or the risk of graft-versus-host 
disease. With respect to transplantation of autologous gene-modified 
HSCs, RIC is almost always indicated, except in certain cases (such 
as SCID), where the gene-modified cells have a significant survival 
advantage.[6] 
The morbidity associated with conditioning regimens is not trivial: 
in the short term, patients suffer complications such as mucositis, 
neutropenia and a high risk of infection, while in the long-term 
risks of sterility, organ damage and secondary tumours can be 
anticipated. Given these safety concerns, several groups have started 
to develop alternative pre-conditioning regimens, which aim to be 
‘chemo-free’ and with significantly improved safety profiles without 
a compromise with regard to HSC engraftment. Moreover, such 
alternatives would provide welcome relief to groups developing gene-
modified HSC treatments for less severe diseases such as HIV, where 
cytotoxic conditioning regimens pose a significant challenge for the 
feasibility of their treatments. Novel approaches in this regard include 
the use of immunotoxins and monoclonal antibodies directed to 
markers expressed on HSCs, such as c-Kit,[29] c-Kit and CD47,[30] and 
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CD45.[31] Impressive HSC depletion in pre-clinical models of up to 
99% has been reported.[30] More recently, CAR T cells against the c-Kit 
antigen on HSCs have also been reported as a promising approach.[32] 
Although these are encouraging preclinical developments, thorough 
clinical testing is still required – we have only been able to identify 
one registered clinical trial in which a monoclonal antibody against 
c-Kit is being used as pre-conditioning in SCID patients receiving 
allogeneic HSCT (NCT02963064). 
Conclusion
The recent approval of ex vivo gene-modified HSC therapies is the 
culmination of decades of work with significant improvements in 
vector technologies and HSCT treatment regimens. These treatments 
are today accepted by the global medical community, and provide a 
new paradigm of curative treatments. However, several improvements 
can still be made to achieve optimal safety and efficacy parameters. 
Gene-editing and transposon systems offer a new dimension for 
genetic modification of patient cells, and hold great promise for 
future application for a variety of diseases. Another hopeful prospect 
is the potential for chemotherapy-free conditioning, which would 
substantially improve treatment quality and lower the barrier to 
entry for novel therapy approvals. Finally, a notable consideration 
for routine application of these treatments is around the topic of 
cost. The approved Strimvelis and Zynteglo therapies cost in excess 
of USD500 000 (~ZAR7 million), which is the result of the cost of 
viral vector manufacturing, cell processing and the application of 
these treatments as personalised therapies. With the future scaling-
up of these treatments, costs are anticipated to decrease over time, 
but are likely to remain unaffordable to the majority of patients in 
low- to middle-income countries. Innovative strategies are required 
to enable global access to these treatments, and to ensure that patients 
in resource-poor communities are not excluded from these exciting 
developments. 
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